[1] Xu MC, Cao CH, Wu P, et al. Advances in cervical cancer: current insights and future directions. Cancer Commun (Lond), 2025; 45, 77−109. doi:  10.1002/cac2.12629
[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024; 74, 229−63. doi:  10.3322/caac.21834
[3] Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet, 2019; 393, 169−82. doi:  10.1016/S0140-6736(18)32470-X
[4] Perkins RB, Wentzensen N, Guido RS, et al. Cervical cancer screening: a review. JAMA, 2023; 330, 547−58. doi:  10.1001/jama.2023.13174
[5] Abu-Rustum NR, Yashar CM, Arend R, et al. NCCN guidelines® insights: cervical cancer, version 1.2024. J Natl Compr Canc Netw, 2023; 21, 1224−33. doi:  10.6004/jnccn.2023.0062
[6] Cibula D, Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023. Virchows Arch, 2023; 482, 935−66. doi:  10.1007/s00428-023-03552-3
[7] Klg A, Priyadharshini B, Vasugi S, et al. Exploring the therapeutic potential of biosynthetic enzymes in cancer treatment: Innovations and implications. Int J Biol Macromol, 2025; 292, 139171. doi:  10.1016/j.ijbiomac.2024.139171
[8] Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol, 2021; 18, 645−61. doi:  10.1038/s41571-021-00521-0